Legal & General Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-163
Closed -$11K – 3727
2022
Q1
$11K Hold
163
– – ﹤0.01% 3392
2021
Q4
$20K Buy
163
+2
+1% +$338 ﹤0.01% 3282
2021
Q3
$23K Hold
161
– – ﹤0.01% 3235
2021
Q2
$44K Buy
161
+35
+28% +$8.83K ﹤0.01% 2995
2021
Q1
$27K Buy
126
+13
+12% +$3.59K ﹤0.01% 3029
2020
Q4
$27K Sell
113
-21
-16% -$2.6K ﹤0.01% 2986
2020
Q3
$14K Buy
134
+38
+40% +$3.46K ﹤0.01% 3110
2020
Q2
$9K Buy
96
+20
+26% +$1.75K ﹤0.01% 3337
2020
Q1
$6K Sell
76
-36
-32% -$3.43K ﹤0.01% 3250
2019
Q4
$9K Buy
112
+5
+5% +$559 ﹤0.01% 3309
2019
Q3
$13K Hold
107
– – ﹤0.01% 3236
2019
Q2
$19K Hold
107
– – ﹤0.01% 3225
2019
Q1
$17K Hold
107
– – ﹤0.01% 3146
2018
Q4
$28K Buy
107
+67
+168% +$13.5K ﹤0.01% 2943
2018
Q3
$10K Hold
40
– – ﹤0.01% 3325
2018
Q2
$9K Buy
+40
New +$11.7K ﹤0.01% 3315

Other funds holding EVLO

Legal & General Group's EVLO Position: Q2 2022 in Review

Legal & General Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 163 shares — an estimated $11K sold.

Legal & General Group first reported a position in EVLO in Q2 2018 and held it in 16 quarters. The position peaked at $44K in Q2 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • Legal & General Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 163 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $11K.
  • Legal & General Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
  • Legal & General Group's Evelo Biosciences, Inc. Common Stock position peaked at $44K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.